Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Long-term quality of life analysis results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial

A Bottomley; M Kicinski; GV Long; M Mandala; VG Atkinson; CU Blank; AM Haydon; S Dalle; A Khattak; MS Carlino; A Meshcheryakov; SK Sandhu; SS Sarda; C Coens; S Suciu; D Grebennik; C Krepler; P Lorigan; C Robert; AMM Eggermont

doi:10.1016/j.annonc.2022.08.043

Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Long-term quality of life analysis results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial

A Bottomley, M Kicinski, GV Long, M Mandala, VG Atkinson, CU Blank, AM Haydon, S Dalle, A Khattak, MS Carlino, A Meshcheryakov, SK Sandhu, SS Sarda, C Coens, S Suciu, D Grebennik, C Krepler, P Lorigan, C Robert, AMM Eggermont

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	S1410-S1411
Number of pages	3
Journal	Annals of Oncology
Volume	33
Issue number	7
DOIs	https://doi.org/10.1016/j.annonc.2022.08.043
Publication status	Published - Sept 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.annonc.2022.08.043

Cite this

Bottomley, A., Kicinski, M., Long, GV., Mandala, M., Atkinson, VG., Blank, CU., Haydon, AM., Dalle, S., Khattak, A., Carlino, MS., Meshcheryakov, A., Sandhu, SK., Sarda, SS., Coens, C., Suciu, S., Grebennik, D., Krepler, C., Lorigan, P., Robert, C., & Eggermont, AMM. (2022). Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Long-term quality of life analysis results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial. Annals of Oncology, 33(7), S1410-S1411. https://doi.org/10.1016/j.annonc.2022.08.043

@article{cb6dd30fe7404d5aa63da320dabdeb8f,

title = "Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Long-term quality of life analysis results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial",

author = "A Bottomley and M Kicinski and GV Long and M Mandala and VG Atkinson and CU Blank and AM Haydon and S Dalle and A Khattak and MS Carlino and A Meshcheryakov and SK Sandhu and SS Sarda and C Coens and S Suciu and D Grebennik and C Krepler and P Lorigan and C Robert and AMM Eggermont",

year = "2022",

month = sep,

doi = "10.1016/j.annonc.2022.08.043",

language = "English",

volume = "33",

pages = "S1410--S1411",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier BV",

number = "7",

}

Bottomley, A, Kicinski, M, Long, GV, Mandala, M, Atkinson, VG, Blank, CU, Haydon, AM, Dalle, S, Khattak, A, Carlino, MS, Meshcheryakov, A, Sandhu, SK, Sarda, SS, Coens, C, Suciu, S, Grebennik, D, Krepler, C, Lorigan, P, Robert, C & Eggermont, AMM 2022, 'Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Long-term quality of life analysis results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial', Annals of Oncology, vol. 33, no. 7, pp. S1410-S1411. https://doi.org/10.1016/j.annonc.2022.08.043

Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Long-term quality of life analysis results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial. / Bottomley, A; Kicinski, M; Long, GV et al.
In: Annals of Oncology, Vol. 33, No. 7, 09.2022, p. S1410-S1411.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma

T2 - Long-term quality of life analysis results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial

AU - Bottomley, A

AU - Kicinski, M

AU - Long, GV

AU - Mandala, M

AU - Atkinson, VG

AU - Blank, CU

AU - Haydon, AM

AU - Dalle, S

AU - Khattak, A

AU - Carlino, MS

AU - Meshcheryakov, A

AU - Sandhu, SK

AU - Sarda, SS

AU - Coens, C

AU - Suciu, S

AU - Grebennik, D

AU - Krepler, C

AU - Lorigan, P

AU - Robert, C

AU - Eggermont, AMM

PY - 2022/9

Y1 - 2022/9

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:000866211602453&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1016/j.annonc.2022.08.043

DO - 10.1016/j.annonc.2022.08.043

M3 - Meeting Abstract

SN - 0923-7534

VL - 33

SP - S1410-S1411

JO - Annals of Oncology

JF - Annals of Oncology

IS - 7

ER -

Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Long-term quality of life analysis results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial

UN SDGs

Access to Document

Other files and links

Cite this